NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN TYPE 1 DIABETES
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE
NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY
FOR IFNalpha KINOID IN TYPE 1 DIABETES
Company intends to continue preclinical development in this indication in 2018
Paris and Boston, December 12th 2017, 07:00 am CET - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced positive initial results from its ongoing proof-of-concept (PoC) preclinical studies with IFNalpha Kinoid for the treatment of Type 1 Diabetes (T1D).
-
A strong production of neutralizing antibodies to IFNalpha following IFNalpha Kinoid administration
-
A twice higher preservation of Langerhans islets[2] is observed in mice treated with IFNalpha Kinoid compared to the control groups.
-
A notable delay in the onset of Type 1 Diabetes in relation to the persistence of anti-IFNalpha neutralizing antibodies
Lesen Sie auch
IFNalpha Kinoid is an anti-interferon-alpha vaccine that is currently in clinical development in several indications. Neovacs previously demonstrated in its Phase I/IIa[3] clinical study of IFNalpha Kinoid in Lupus that the persistence of neutralizing antibodies for several years can be achieved with the Company's vaccine candidate and is also capable of neutralizing the Interferon signature. A Phase IIb study is currently ongoing with IFNalpha Kinoid for the treatment of Lupus.